Therapy focus areas, types and product pipelines
More than half of the respondents work in companies with a focus on oncology, and 1 in 4 respondents work in companies with a focus on cardiovascular or autoimmune disorders.
63% of the respondents say they are working on both autologous and allogeneic products, however allogeneic products are the most popular cell therapy type.
More than half of respondents have cell therapy clinical trials in their preclinical or phase I stage, while a third are running trials in either discovery or phase II.
More than half of the respondents say their companies have gene-enabled cell therapies such as CAR-T and CAR-NK in their production pipeline.
Another 42% indicate that their companies are focusing on non-modified cell therapies such as MSCs and TILs, and just under 1 in 3 report that their companies are working on production of iPSC-based cell therapies.
57% of respondents who are developing gene-edited cell therapies say that they are carrying out their viral vector and cell therapy manufacturing with the same partner.
38% of respondents who are developing non-modified cell therapies say that their cell type did not require gene editing for the disease their programs are focused on.
1 in 4 said that they chose their product type to simplify supply chain processes.
56% of respondents who are focused on iPSCs say that their companies are developing their own custom bank, while 44% say that they are using a commercially available iPSC GMP bank.
